Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....
Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s...
Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...
Charles River Laboratories International, Inc. CRL has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support...
Henry Schein, Inc. HSIC registered adjusted earnings per share (EPS) of $1.22 in the third quarter of 2024, down 7.6% from the year-ago figure. However, the metric exceeded the Zacks Consensus Estimate...
Bio-Rad Laboratories, Inc. BIO posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year...
Wall Street is sitting on its hands on Monday and Tuesday waiting for Alphabet, Microsoft, Apple, Amazon, and other mega-cap technology stocks to report their results in the final week of October.See the...
Walgreens Boots Alliance, Inc. WBA delivered adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2024, down 41.8% from the year-ago quarter’s figure (down 40.8% at constant...
Penumbra, Inc. PEN is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company’s robust portfolio expansion looks promising. However, the impact...